Quiver Bioscience secured $0.91 million investment to enhance its CNS genetic medicine discovery platform and improve safety prediction for antisense oligonucleotide therapeutics. The company’s portfolio includes programs advancing precision treatments for both common and rare neurological disorders, including Dup15q syndrome, Fragile X syndrome, and KCNT1-related epilepsy.
